| Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. | |
| | |
MedLine Citation:
|
PMID: 11801698 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hexamethylpropyleneamine oxime (HMPAO) SPECT and 18F-FDG PET depict similar aspects of perfusion and metabolic abnormalities in Alzheimer's disease (AD), but the correspondence between them is not known in detail. We therefore used statistical parametric mapping to detect and compare abnormal brain areas objectively and quantitatively. METHODS: Twenty-six patients with probable AD (mean age +/- SD, 66 +/- 9 y; mean Mini-Mental State Examination score, 22.5 +/- 4.2) and 6 nondemented healthy volunteers (mean age, 63 +/- 11 y) were studied with HMPAO SPECT and 18F-FDG PET. All images underwent the same processing steps, including 12-mm gaussian smoothing, spatial normalization, and z transformation with respect to normal average and SD. Thresholding of z maps was used to detect abnormal voxels. RESULTS: The overall correlation between PET and SPECT across the entire brain was significant but not close (average r = 0.43). The best correspondence was found in the temporoparietal and posterior cingulate association cortices. There, the number of abnormal voxels for PET correlated strongly with the number for SPECT (r = 0.90 at a z threshold of -2.25), but tracer uptake reductions were significantly more pronounced for PET than for SPECT. Discordant findings were most frequently seen in the temporobasal and orbitofrontal areas (PET low, SPECT high) and in the cerebellum, parahippocampal cortex, and midcingulate cortex (PET high, SPECT low). The correlation between dementia severity and the number of abnormal voxels was closer for PET than for SPECT. Separation of patients from healthy volunteers by counting the number of abnormal voxels was possible over a much wider range of z thresholds with PET than with SPECT. CONCLUSION: Correspondence between 18F-FDG PET and HMPAO SPECT is limited to the main finding of temporoparietal and posterior cingulate functional impairment in mild to moderate AD. The distinction between healthy volunteers and patients is less sensitive to threshold selection with PET than with SPECT, and findings in the frontal, temporobasal, and temporomesial cortices and in the cerebellum may differ between the 2 techniques. |
| | |
Authors:
|
Karl Herholz; Helge Schopphoff; Mathias Schmidt; Rüdiger Mielke; Wolfgang Eschner; Klemens Scheidhauer; Harald Schicha; Wolf-Dieter Heiss; Klaus Ebmeier |
Related Documents
:
|
9544688 - Pulmonary spect imaging and the stripe sign. 16407818 - Imaging reporter genes for cell tracking with pet and spect. 23582588 - Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (p904) and... 17203458 - Spect-ct fusion: a new diagnostic tool for endocrinology. 23149778 - Using four-dimensional computed tomography images to optimize the internal target volum... 8227578 - Mra in the evaluation of ec-ic bypass patency. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of nuclear medicine : official publication, Society of Nuclear Medicine Volume: 43 ISSN: 0161-5505 ISO Abbreviation: J. Nucl. Med. Publication Date: 2002 Jan |
Date Detail:
|
Created Date: 2002-01-21 Completed Date: 2002-02-26 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0217410 Medline TA: J Nucl Med Country: United States |
Other Details:
|
Languages: eng Pagination: 21-6 Citation Subset: IM |
Affiliation:
|
Neurologische Universitätsklinik, Köln, Germany. karl.herholz@pet.mpin-koeln.mog.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Alzheimer Disease / radionuclide imaging* Brain / radionuclide imaging* Case-Control Studies Female Fluorodeoxyglucose F18 / diagnostic use Humans Male Radiopharmaceuticals / diagnostic use Technetium Tc 99m Exametazime / diagnostic use Tomography, Emission-Computed* Tomography, Emission-Computed, Single-Photon* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 100504-35-6/Technetium Tc 99m Exametazime; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Heterogeneity of cardiac sympathetic nerve activity and systolic dysfunction in patients with hypert...
Next Document: Color and power Doppler sonography versus DMSA scintigraphy in acute pyelonephritis and in predictio...